Deutsche Bank: Buy Enanta Pharma And Its Near-Term Upside
In a report published Monday, Deutsche Bank analysts imitated coverage of Enanta Pharmaceuticals, Inc (NASDAQ: ENTA) with a Buy rating and a price target of $42.
Enanta is a small cap HCV company that is partnered with big cap Abbvie selling Viekira.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.